LTR Pharma (ASX:LTP) said the first patient-specific prescriptions for ROXUS, its intranasal medication for erectile dysfunction support, received through Shed's men's health telehealth platform Mavrox, have been fulfilled in the US, according to a Tuesday Australian bourse filing.
Strive Pharmacy set up the operational systems required to receive, compound and fulfil valid patient-specific ROXUS prescriptions.
Its shares climbed 1% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.